Fungal Foot Infections Drug Development Pipeline Review, 2018
Summary Onychomycosis and athlete’s foot are non-life threatening fungal infections that most commonly affect the toenails and the feet respectively. Athlete’s foot affects 15% of the population globally, with males being more commonly affected than females. Onychomycosis affects roughly 10% of the global adult population.
There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology.
There are a total of 25 products in development across these indications, by 24 companies.
This report “Fungal Foot Infections Drug Development Pipeline Review, 2018” provides an overview of the onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis) pipeline landscapes. The report provides comprehensive information on the therapeutics under development and key players active in these two indications, and features dormant and discontinued projects.
Scope - Which companies are the most active within each pipeline? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each - Analyze the companies currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Our reports have been used by over 10K customers, including:
111 pages •
By Euromonitor International
• Oct 2020
The measures taken to control COVID-19 have had a significant impact on consumer health in Portugal, with consumers pushed to take a more proactive approach to their health. The impact started to be felt in March with consumer fears and concerns being heightened by reports of widespread cases of COVID-19 in neighbouring Spain.
Analgesic Medicine Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.